Menarini has secured EU approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs and the first innovation in endocrine the
Menarini subsidiary Stemline Therapeutics has won FDA approval for Orserdu, the first in a new class of oral selective oestrogen receptor degrader (SERD) drugs that provid
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl